Polypharmacy and the risk of drug-drug interactions in patients with rheumatoid arthritis

Nikola Krstić; Nikola Stefanović; Milan Petronijević; Ivana Damnjanović

doi:10.5937/afmnai41-45883

Original article

Published: 01.12.2023.

<< Prev | Next >>

PDF

https://doi.org/10.5937/afmnai41-45883

Polypharmacy and the risk of drug-drug interactions in patients with rheumatoid arthritis

Abstract

Polypharmacy can increase the risk of side effects and cause adverse drug interactions with a significant impact on the course of the basic disease. The aim of the study was to determine the frequency of polypharmacy and examine its impact on the risk of drug-drug interactions in patients with rheumatoid arthritis (RA). The research was conducted in the form of a retrospective cross-sectional study. The study included 131 patients diagnosed with RA, treated during 2019 and 2020. Demographic data and clinical characteristics of the subjects were collected from the medical documentation (presence of comorbidities, prescribed therapy and number of drugs). In the study, polypharmacy was defined as the use of more than five drugs, regardless of the length of therapy. The data analysis of the therapy used by patients showed that 84 subjects (64.12%) used 5 - 9 drugs, both for the treatment of primary and for the treatment of other present acute and chronic diseases. The analysis of the collected results identified potential interactions in 86 respondents (65.65%), while the total number of potential interactions was 164. The most common potential interactions were serious (73.78%). Analyzing the obtained results, it appears that aceclofenac is the drug that has the potential to enter into the largest number of interactions with the drugs used in the therapy of RA. Given the wide range of available drugs and therapeutic modalities used in the treatment of RA, it is necessary to choose the right combination of drugs in order to achieve the desired therapeutic outcomes and minimize potential drug-drug interactions.

Keywords:

polypharmacy,

drug-drug interactions,

rheumatoid arthritis

References

McEwen J, Purcell PM, Hill RL, Calcino LJ, Riley CG. The incidence of pancytopenia in patients taking leflunomide alone or with methotrexate. Pharmacoepidemiology and Drug Safety. 2007;16(1):65–73.

Bagatini F, Blatt CR, Maliska G, Trespash GV, Pereira IA, Zimmermann AF, et al. Potenciais interações medicamentosas em pacientes com artrite reumatoide. Revista Brasileira de Reumatologia. 51(1):29–39.

Gomides APM, Albuquerque CP, Santos ABV, Amorim RBC, Bértolo MB, Júnior PL, et al. High Levels of Polypharmacy in Rheumatoid Arthritis—A Challenge Not Covered by Current Management Recommendations: Data From a Large Real-Life Study. Journal of Pharmacy Practice. 2021;34(3):365–71.

Ma SN, Zaman Huri H, Yahya F. <p>Drug-related problems in patients with rheumatoid arthritis</p> Therapeutics and Clinical Risk Management. Volume 15:505–24.

Pflugbeil S, Böckl K, Pongratz R, Leitner M, Graninger W, Ortner A. Drug interactions in the treatment of rheumatoid arthritis and psoriatic arthritis. Rheumatology International. 2020;40(4):511–21.